What's Coming Next: The GLP-1 Pipeline for 2026 and Beyond
Triple agonists with 24% weight loss. Combination therapies. Monthly injectables. Oral pills that rival injections. The next generation of GLP-1-based medications is already in clinical trials — and the results are remarkable.
If you think the current GLP-1 medications are impressive, the pipeline is even more exciting. Pharmaceutical companies are racing to develop next-generation drugs that produce greater weight loss, have fewer side effects, come in more convenient formats, and target additional health conditions. Here's every pipeline drug worth watching.
The Big Pipeline Drugs
Why it matters: Retatrutide adds a third receptor — the glucagon receptor — to the dual agonism already seen in tirzepatide. Glucagon receptor activation increases energy expenditure (calorie burning) on top of the appetite suppression from GLP-1 and the insulin-sensitizing effects from GIP. The result: the most weight loss ever seen in a clinical trial for an obesity drug. NEJM
Phase 2 data: At the highest dose (12mg), participants lost an average of 24.2% of their body weight over 48 weeks. Over 50% of patients lost more than 25% of their body weight. For reference, the current best-in-class (tirzepatide) averages about 22.5%.
Timeline: Seven Phase 3 trials are expected to complete in 2026. Eli Lilly could file for FDA approval as early as this year, with potential approval in 2027.
Why it matters: Rather than adding more gut hormone receptors, Novo Nordisk's approach combines semaglutide with an amylin analog. Amylin is a hormone co-secreted with insulin that contributes to satiety and slows gastric emptying through a different pathway than GLP-1. The combination aims to produce additive weight loss effects.
Phase 2 data: CagriSema achieved approximately 22.7% body weight loss — outperforming semaglutide 2.4mg alone by a meaningful margin.
Timeline: Phase 3 REDEFINE trials are ongoing, with results expected through 2026-2027. FDA filing likely in 2027.
Why it matters: Unlike oral semaglutide (which is a peptide requiring the SNAC absorption enhancer), orforglipron is a small molecule — easier to manufacture, potentially more stable, and it outperformed oral semaglutide in head-to-head trials. If approved, it gives patients a second oral option.
ACHIEVE-3 data: Orforglipron 36mg reduced A1C by 2.2% (vs. 1.4% for oral semaglutide) and produced 19.7 lbs of weight loss (vs. 11.0 lbs). That's 73.6% greater relative weight loss.
Timeline: FDA decision expected April 10, 2026.
Why it matters: Novo Nordisk's amycretin combines GLP-1 and amylin receptor agonism in a single oral molecule. Early phase data showed impressive weight loss results, and if it scales to later trials, it could represent the most effective oral obesity medication.
Status: Phase 2, with larger trials underway. Timeline to market: 2028-2029 at earliest.
Why it matters: Current GLP-1 injectables are weekly. Several companies are developing monthly formulations that would reduce injection frequency to just 12 times per year. Pfizer acquired Metsera's MET-097i in November 2025, signaling serious commitment to the space.
Status: Early clinical development. Timeline to market: 2028+.
The Full Pipeline at a Glance
| Drug | Company | Mechanism | Best Weight Loss Data | Stage |
|---|---|---|---|---|
| Retatrutide | Eli Lilly | Triple (GLP-1/GIP/Glucagon) | -24.2% | Phase 3 |
| CagriSema | Novo Nordisk | Semaglutide + amylin | -22.7% | Phase 3 |
| Orforglipron | Eli Lilly | Oral GLP-1 (small molecule) | ~15% | PDUFA Apr 2026 |
| Amycretin | Novo Nordisk | Oral GLP-1 + amylin | TBD (promising) | Phase 2 |
| MET-097i | Pfizer/Metsera | Monthly injectable GLP-1 | TBD | Early clinical |
Each generation of GLP-1-based medications is producing more weight loss, better tolerability, more convenient dosing, and broader health benefits. What started as a diabetes drug producing 5-7% weight loss has evolved into a platform technology delivering 20-25%+ — and the trajectory isn't slowing down.
What This Means for Patients Today
If you're waiting for the "perfect" GLP-1 medication before starting treatment, consider this: the medications available right now are already among the most effective drugs ever developed for obesity. Semaglutide and tirzepatide have robust, multi-year clinical evidence supporting their use.
The pipeline drugs will be even better — but they're also years away from your pharmacy shelf. Starting treatment with what's available today means you can begin improving your health now, and transition to next-generation options when they arrive.
The future of obesity medicine is extraordinarily bright. More effective treatments, more delivery options, better pricing, and expanding insurance coverage are all converging to create the most patient-friendly treatment landscape this field has ever seen.
Explore GLP-1 Providers
Ready to get started? These verified telehealth providers offer GLP-1 programs with medical oversight and home delivery:
Personalized GLP-1 treatment plans with licensed medical providers and home-delivered medications.
CPA: $250
Comprehensive GLP-1 weight management programs with licensed providers and home delivery.
CPA: $350
Compounded semaglutide and tirzepatide programs with full medical consultation and ongoing support.
CPA: $350
Telehealth weight loss programs with compounded GLP-1 medications and clinical oversight.
CPA: $300
Medical weight management platform with compounded GLP-1 options and clinical oversight.
CPA: $228
Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content or provider selection.
Sources
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. NEJM. 2023;389:514-526. PubMed
- Drucker DJ. The expanding landscape of GLP-1 medicines. Nature Medicine. 2026;32:47-57. nature.com
- Eli Lilly. ACHIEVE-3 trial results and orforglipron NDA filing. 2025-2026. lilly.com
- Novo Nordisk. CagriSema Phase 2 results and REDEFINE trial program. novonordisk.com
- ClinicalTrials.gov. Retatrutide, CagriSema, orforglipron, and amycretin trial registrations. clinicaltrials.gov
- NBC News. Weight loss drug outlook for 2026: pills, pipelines, and pricing. January 2026. nbcnews.com